Gilead Sciences, Inc. (GILD) vs Eli Lilly and Company (LLY)
Gilead Sciences, Inc. and Eli Lilly and Company are both Drug Manufacturers General companies. Eli Lilly and Company is the larger, with a market value of $1.11T against $183.2B — 6.1× the size. Gilead Sciences, Inc. has negative trailing earnings, so its P/E is not meaningful; Eli Lilly and Company trades at 39.7×. Eli Lilly and Company grew revenue faster over the last twelve months: 49.6% against 5.52%. Eli Lilly and Company has the higher net margin (33.5% vs −10.6%) and the higher return on invested capital (26.3% vs −4.48%). Both pay a dividend; Gilead Sciences, Inc. yields more (4.27% vs 0.72%). Across the 22 metrics below, Eli Lilly and Company leads on 13 and Gilead Sciences, Inc. on 9.
Valuation
Profitability
| Metric | GILD | LLY | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 79.59% | 83.40% | 72.77% |
| Operating margin | (8.20%) | 42.22% | 18.90% |
| Net margin | (10.64%) | 33.53% | 8.27% |
| Free cash flow margin | 42.50% | 22.83% | 17.25% |
| Return on equity | (20.68%) | 102.29% | 6.97% |
| Return on assets | (6.17%) | 21.97% | 2.76% |
| Return on invested capital | (4.48%) | 26.33% | 6.30% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack